The added value of relative amide proton transfer (rAPT) to advanced multiparametric MR imaging for brain glioma characterization

Abstract

Background

Differentiation between the grades of brain gliomas is a crucial step in the management of patients. The gold standard technique for grading is biopsy but MR imaging may play a more substantial role as a non-invasive method by using promising molecular sequences. Our purpose was to assess the added value of the relative amide proton transfer signal [rAPT] to advanced multiparametric MRI protocol.

Methods

We enrolled a pathologically confirmed 102 patients with low-grade glioma [n = 38] and high-grade glioma [n = 64] who underwent advanced multiparametric MRI protocol on the same scanner. The protocol included anatomic, diffusion, MRS, and perfusion sequences. The newly added sequence was Amide proton transfer. The rAPT values of all lesions were investigated by two neuroradiologists to assess the inter-rater agreement of using interclass correlation coefficient [ICC]. HGGs demonstrated significantly higher mean values of relative cerebral blood volume (rCBV), choline to creatine ratio (Cho/cr), and rAPT with lower Apparent diffusion coefficient (ADC) values compared to LGGs. ROC analyses revealed medium to high diagnostic performance with an AUC of 0.941 for rAPT, 0.907 for mean ADC, and 0.906 for rCBV. Discriminant function analysis of two models, the first one included mean ADC, rCBV, and Cho/Cr, while in the second Model, we added rAPT to them. Model two demonstrated higher accuracy and a significant difference in the AUC after adding the rAPT. The inter-rater agreement was reasonable (ICC 0.61).

Conclusions

rAPT adds significant value to multiparametric MRI for distinguishing LGG from HGG.

Background

Gliomas are the most common primary tumors of the central nervous system [1]. Differentiating low-grade glioma [LGG] from high-grade glioma [HGG] is crucial for prognosis and management [2].

Biopsy with histopathology is the current gold standard examination for discriminating gliomas. However, the histopathological result depends on biopsy conditions which have drawbacks, including being invasive, the intratumoral histological heterogeneity and edema influencing it, and the possibility of exhibiting sampling errors, which may all affect the actual tumor grade [3].

Magnetic resonance imaging is usually done preoperatively for diagnosis as a non-invasive procedure [4]. The pattern of enhancement is different between HGGs and LGGs, where the former shows mild enchantment. However, approximately 14–45% of HGGs show no enhancement, whereas about 20% of enhanced gliomas were histologically proven to be LGGs, as the degree of enhancement might be caused by disruption of the blood–brain barrier rather than neovascularization. Therefore, the accurate grading of gliomas using traditional MRI is still challenging [5, 6].

Dynamic contrast-enhanced MRI [DCE], perfusion, susceptibility-weighted imaging, diffusion-weighted imaging [DWI], MR spectroscopy [MRS], and intravoxel incoherent motion are advanced MRI techniques that are used for glioma grading [7, 8]. Despite being useful, DCE MRI relies on gadolinium contrast, but few complications were reported as nephrogenic systemic fibrosis may increase in patients with impaired renal function or acclamation of contrast in the brain of a normal population if there are repeated administrations [9].

In MRS, increases in choline [Cho]-containing compounds are markers for accelerated cell proliferation, as they reflect increased protein expression and proteolysis [7, 8]. Nevertheless, its accuracy in differentiation is erratic because it is operator-dependent on choosing a voxel place, and this technique does not involve the whole tumor [10]. So, in our advanced protocol, we added a new technique which is Amide proton transfer [APT].

The Amide proton transfer [APT] is a promising molecular-based MRI technique as previous studies have indicated that APT signals could be used to assess brain tumors due to overexpressed mobile protein and peptide concentrations [11,12,13]. APT is a non-invasive technique that does not require contrast administration. It could be used as a substitute for contrast-based MRI, especially in patients with contraindications for a contrast agent. APT also has the practical advantage that acquisition can be immediately repeated in case of suboptimal image quality, which is not the case with perfusion studies [14]. Several studies showed that HGGs had higher APT signal intensity than LGGs [15,16,17], but a limited number of studies assessed the relative APT signal [rAPT]of brain tumor versus normal brain tissue but with no clear cutoff value [18, 19].

In this study, we evaluated the added value of rAPT to multiparametric MRI in assessing brain gliomas.

Methods

This prospective cohort study was approved by our institution's ethical committee -FWA 000017585- FMASU R210/2021. Our inclusion criteria were adult patients ranging from 18 to 83 years old, undergoing multiparametric MR imaging and APT in the same scanner. The HGGs or LGGs are confirmed by histopathology. The excluded patients were those who had motion artifacts, impaired renal functions, or lack of final diagnosis.

The preoperative MR imaging data of 135 patients with gliomas were identified between December 2020 and April 2022. Out of these patients, ten patients were excluded due to motion artifacts on imaging, thirteen patients were excluded due to impaired renal functions, and ten others were excluded due to lack of final diagnosis.

The histopathologic diagnosis was determined by histopathology with biopsy specimens or resections by one neuropathologist, who was blinded to the imaging findings. The patients were divided into two groups including low-grade [1 and 2] and high-grade [3 and 4] gliomas based on the pathological results.

Studies were performed on a 3.0-T clinical scanner [Magnetom Skyra, Siemens]. The detailed imaging parameters for advanced multiparametric sequences including APT are shown in Table 1. APT imaging was acquired using the two-dimensional single-shot fast spin echo planner imaging [EPI] For the APT quantification, after water frequency-shift correction, magnetization transfer component, and the APT [Δω = 3.5 ppm] component, asymmetrical MT ratio [MTRasym] analysis was performed according to previous studies. The DWI was performed in the axial plane with a single-shot spin-echo planar imaging sequence of b values; 0 and 1000 [s/mm²]. The apparent diffusion coefficient (ADC) was calculated by mono-exponential fitting with the pair of b-values.

Table 1 Imaging parameters

The acquired data were transferred from the scanner to a workstation for analysis and postprocessing. Region-of-interests (ROIs) for HGG were manually drawn on post-contrast images and matched by the interlink lines to FLAIR, ADC, cerebral blood volume (CBV), and APT maps. For LGG and or non-enhancing lesions ROIs were manually drawn on FLAIR and matched to post-contrast images, ADC, cerebral blood volume (CBV), and APT map (Fig. 1). Two neuroradiologists experts of 10- and 40 years’ experience calculated the rAPT independently by dividing the mean value of the APT signal intensity of the lesion by the mean APT value of normal white matter on the contralateral side. Readers were aware that they must avoid necrotic regions, hemorrhage, obvious artifacts, or signals from a blood vessel, during drawing the ROI as this can cause substantial reading artifacts. We calculated the relative CBV values (rCBV) by normalization to the contralateral normal-appearing gray matter.

Fig. 1

A 44-year-old female patient presented with vertigo and pathologically proved low-grade glioma at the right cerebellar peduncle with MR images as follows: a Axial FLAIR image shows a well-defined high signal intensity lesion within the right cerebellar peduncle with no surrounding edema, b ADC map shows no true diffusion restriction within the lesion, c CVB map shows iso to hypoperfused lesion, and d-APT map also shows iso-intensity of the lesion compared to contralateral side with rAPT = 0.97 (Note that the interlink lines are used to draw ROIs)

Statistical analysis

• The sample size was calculated using MedCalc Statistical Software version 15.8 (MedCalc Software bvba, Ostend, Belgium; https://www.medcalc.org; 2015), setting the type-1 error (α) at 0.05 and the power (1-β) at 0.8. Results from a previous study (C.su et al., 2017) reported an AUC to differentiate between LGG and HGG of 0.791. Based on these values the calculated sample size was at least 18 high-grade and at least eighteen low-grade cases achieving an AUC of 0.79 with a 95% confidence interval of 0.3.

• Data were analyzed using Statistical Package for Social Science [IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.]. Quantitative parametric variables were described using the range, mean, and standard deviation. Qualitative variables were described using numbers and percentages. The first analysis was done using an independent sample t-test that compared the mean of continuous variables. P value < 0.05 was considered statistically significant for all statistical methods. Receiver operator characteristic [ROC] curve analysis was then performed to determine the optimal cutoff value of variables that passed the first analysis.

• A discriminant function analysis [DFA] was then used for variables that achieved significant results in this second analysis [p value < 0.05], and the variables were classified into two models: Model 1 multiparametric study which included ADC, MRS, CH/Cr, and rCBV, and model 2 multiparametric study which included rAPT, ADC, MRS, CH/Cr, and rCBV. The diagnostic performance of the categorical variable was performed using cross-tabulation. The sensitivity, specificity, and accuracy were then calculated.

• The eigenvalue was calculated to determine the efficiency of all variables in the model in predicting brain glioma grading. Standardized DFA coefficients were also calculated to demonstrate the unique contribution of each predictor variable to the function. Paired-Sample Area Difference under the ROC Curves was conducted to determine the diffidence between the AUC of both models.

• We determined the inter-rater agreement using the intra-class correlation coefficient (ICC) (20). ICC scores below 0.4 were considered as poor agreement, 0.4–0.6 as reasonable,0.6–0.7 as good, and 0.7–1 as excellent [20].

Results

The total number of patients was 102 [61 males and forty-one females], 38 of them had LGGs and 64 had HGGs. The mean age of patients was 41.7 years, [range 18–83 years]. An observation was noted that the incidence of HGG increased with age. The rest of the demographic and general characteristics of patients are described in Table 2.

Table 2 Demographic and general characteristics of brain tumors

Hemorrhage, peritumoral edema, central necrosis, and ring contrast enhancement were analyzed in both HGGs and LGGs on conventional and post-contrast images using an independent t-test. Hemorrhage was observed in 45.3% of HGGs and 5.3% of LGGs. About 67.2% of HGGs and 26.3% of LGGs showed peritumoral edema. We observed central necrosis in 62.5% of HGGs and 26% of LGGs. Ring post-contrast enhancement was seen in 54.7% of HGGs and 7.9% of LGGs.

To assess the reliability and consistency of rAPT measurements between the two readers, Inter-rater agreement was evaluated using the intra-class correlation coefficient (ICC) which revealed a reasonable value of 0.61.

Using an independent sample t-test showed significantly higher mean values of rCBV, Cho/cr, and rAPT (Figs. 2, 3), as well as lower ADC values in HGGs compared to LGG tumors. The mean value of rAPT in HGGs was 2.12 ± 0.11 while in LGGs was 1.46 ± 0.27. HGG mean value of rCBV was 5.38 ± 2.99while the LGGs were 2.12 ± 0.49. The mean value of Cho/cr in HGGs was 3.59 ± 3.31 while in LGGs was 1.65 ± 0.60. The mean value of ADC in HGGs was 0.97 ± 0.17 while in LGGs was 1.39 ± 0.26.

Fig. 2

A 39-year-old male patient presented with a headache and was pathologically proven low-grade glioma at the left temporal lobe with MR images as follows: a FLAIR shows the high signal intensity of the focal lesion (arrow), b ADC map shows no true diffusion restriction of the lesion (arrow), c axial post-contrast image shows homogeneous faint post-contrast enhancement (arrow), d MRS shows low Cho/cr ratio, e- CVB map shows hypoperfusion of the lesion, f-APT map shows iso intense signal of the lesion with rAPT = 1.1

Fig. 3

A 56-year-old female patient presented with a headache and was pathologically proven left temporal high-grade glioma with MR images as follows: a axial post gadolinium T1 WI shows marginal enhancement of the lesion, b Axial FLAIR images show a rather well-defined hyperintense lesion with surrounding vasogenic edema, c APT image shows a high-intense signal of the lesion compared to the contralateral normal white matter with rAPT = 1.43, d MRS shows high Cho/cr ratio

The ROC (Table 3) was used to analyze the discriminatory abilities of rAPT, mean ADC, rCBV, and Cho/cr values which revealed medium to high diagnostic performance of all parameters. The area under the curve [AUC] was 0.941 for rAPT, 0.907 for mean ADC, and 0.906 for rCBV with cutoff values of 1.315, 1.12, and 2.36, respectively.

Table 3 ROC shows Cut off value of rAPT, ADC,rCBVand Cho/cr for predicting high-grade tumor

To assess the added value of rAPT to multiparametric MRI, we used the discriminant function analysis [DFA] test between two models, where the first one included the multiparametric MRI without rAPT, while in the second one rAPT was added to them. As demonstrated in (Table 4). There was an increase in the eigenvalue of the second model after adding the rAPT, with an increase in diagnostic performance from 83.33 to 94.11 (Table 5). Moreover, Table 6 illustrates the higher accuracy and significant increase in the AUC of the second model.

Table 4 Discriminant function analysis [DFA] between two multiparametric models

Table 5 Diagnostic performance of discriminant function analysis between two multiparametric models

Table 6 Difference between AUC of model 1 and model 2

Discussion

APT imaging is a novel MRI technique that provides molecular information predominantly based on the amide protons in cellular proteins and peptides in the intracellular and extracellular spaces [15]. Higher peptide and protein concentrations usually result from higher cell density in HGGs [16, 17]. Kang et al. [15], Schön et al. [16], Sakata et al. [17], and Sotirios et al. [11] studies showed that HGGs had higher APT signals than LGGs. Recent limited studies assessed the relative APT signal of primary and secondary brain tumors compared to normal brain tissue but neither of them sets a clear cutoff value of rAPT for HGGs or LGGs [18, 19, 21].

Our primary aim was to assess the added value of relative APT [rAPT] to multiparametric MRI brain to distinguish LGGs and HGGs so we first assessed the inter-reader agreement using the intra-class correlation coefficient. There was a reasonable inter-rater agreement of rAPT values (ICC = 0.61) that can be explained by the difference in the experience of our readers.

As regards the rAPT values our results showed that HGGs had significantly higher rAPT than LGGs. This was consistent with the results of the previous two studies which were done recently to assess APT signals in different brain tumors versus normal white matter [18, 19].

Then we assessed the diagnostic performance of rAPT using the ROC which revealed medium to high diagnostic performance of rAPT with AUC of 941 and cutoff value of 1.31, achieving a sensitivity of 95% and specificity of 84%. The earlier studies did not set a cutoff value of rAPT to differentiate grades of glioma, but one of them compared the APT signal of glioblastoma to normal brain tissue, achieving 100% sensitivity and 80% specificity with an AUC of 960 [18].

Currently, different imaging techniques are applied to differentiate HGGs and LGGs, such as DWI, rCVB, and MRS, but many authors investigated the added value of APT as Choi et al. [22] study revealed that discrimination abilities of the APT, ADC, and rCBV values were not significantly different but did not investigate the rAPT.

Our results proved that rAPT had a comparable ability to predict tumor grade as rCBV and had better discrimination ability than the ADC, which was also consistent with Lingl et al. [18] differentiation of glioblastoma from the normal brain tissue. Durmo et al. [19] study demonstrated also that APT was a better predictor than ADC in differentiating LGGS from HGGs. This could be explained by the overexpression of various proteins in the extracellular matrix in high-grade glioma and in turn, increase the fluid mobility within the extracellular environment. Thus, causes higher ADC in the enhancing area than those with lower ADC, but an increase in the mobile peptides will increase APT-related signal [23, 24].

In addition, rAPT showed comparable diagnostic capability for grading brain tumors as Cho/cr ratios on MRS. Sakata et al. [25] study also concluded that MRS and APT imaging had a comparable diagnostic capability for grading brain tumors.

Choi et al. [22] investigated the added value of APT when used with ADC which showed significant improvement in the discrimination ability of brain glioma compared to the ADC alone with AUC 910 versus 888.

To date, no studies investigated the added value of rAPT to multiparametric MRI brain protocol including rCVB, ADC, and MRS. We used the DFA, and we observed a significant increase in the diagnostic performance of the multiparametric protocol when the rAPT was added, increasing the AUC from 819 to 932.

The strength of our study was achieved by enrolling a large sample size [more than one hundred], Also we are suggesting a new parameter called rAPT which was not investigated in depth in previous studies and has comparable results to other advanced techniques and can be used without contrast injection. Nevertheless, we also had limitations. First, it was a single-centered study. Thus, conducting multi-centric studies with larger data sets is required to validate the results. Moreover, a manual ROI-based approach was performed for analysis in our research.

Conclusions

In conclusion, rAPT is a useful non-invasive imaging biomarker that significantly increases the diagnostic performance of the multiparametric protocol. We believe that the rAPT techniques can be a valuable tool if a patient refuses a contrast injection or has contraindications for a contrast agent. Furthermore, it can be used in research to differentiate post-treatment changes in glioma versus residual tumoral tissue.